In Dr. Kalantar-Zadeh's June 2020 ERA-EDTA presentation on BETonMACE, a bullet point on the slide 24 "Limitations of the CKD study" states "eGFR changes over time were not different." So it sounds like there wasn't strong enough data to support a claim of statistically significant change in eGFR in the CKD sub-study.

In regards to changes in alkaline phosphatase.....in addition to the data you cite at 2 and 24 weeks for the entire BETonMACE population, Resverlogix shared data at 100 weeks in their detailed presentation last November (slides 53 and 54) that showed sustained apabetalone-mediated decrease in alkaline phosphatase. However, as far as I know there has not been any on-treatment change in alkaline phosphatase data shared yet for the CKD subgroup....just baseline as you mentioned.

BDAZ